Evidence map›Paper›PMID 29487690›Full record

ArticleOncotarget2018

Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model.

Kentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, Kentaro Miyake, Masuyo Miyake, Yunfeng Li, Scott D Nelson, Sarah M Dry, Arun S Singh, Irmina A Elliott and 9 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Kentaro IgarashiAntiCancer, Inc., San Diego, California, USA.
Kei KawaguchiAntiCancer, Inc., San Diego, California, USA.
Tasuku KiyunaAntiCancer, Inc., San Diego, California, USA.
Kentaro MiyakeAntiCancer, Inc., San Diego, California, USA.
Masuyo MiyakeAntiCancer, Inc., San Diego, California, USA.
Yunfeng LiDepartment of Pathology, University of California, Los Angeles, California, USA.
Scott D NelsonDepartment of Pathology, University of California, Los Angeles, California, USA.
Sarah M DryDepartment of Pathology, University of California, Los Angeles, California, USA.
Arun S SinghDivision of Hematology-Oncology, University of California, Los Angeles, California, USA.
Irmina A ElliottDivision of Surgical Oncology, University of California, Los Angeles, California, USA.
Tara A RussellDivision of Surgical Oncology, University of California, Los Angeles, California, USA.
Mark A EckardtDepartment of Surgery, Yale School of Medicine, New Haven, Connecticut, USA.
Norio YamamotoDepartment of Orthopaedic Surgery, Kanazawa University, Kanazawa, Japan.
Katsuhiro HayashiDepartment of Orthopaedic Surgery, Kanazawa University, Kanazawa, Japan.
Hiroaki KimuraDepartment of Orthopaedic Surgery, Kanazawa University, Kanazawa, Japan.
Shinji MiwaDepartment of Orthopaedic Surgery, Kanazawa University, Kanazawa, Japan.
Hiroyuki TsuchiyaDepartment of Orthopaedic Surgery, Kanazawa University, Kanazawa, Japan.
Fritz C EilberDivision of Surgical Oncology, University of California, Los Angeles, California, USA.
Robert M HoffmanAntiCancer, Inc., San Diego, California, USA.
University of California, Los Angeles · USKanazawa University · JPUniversity of California, San Diego · USAntiCancer (United States) · USYale University · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
NCI NIH HHS P30 CA016042
6 · The paper itself

Abstract

Relapsed osteosarcoma is a recalcitrant tumor. A patient's cisplatinum (CDDP)-resistant relapsed osteosarcoma lung metastasis was previously established orthotopically in the distal femur of mice to establish a patient-derived orthotopic xenograft (PDOX) model. In the present study, the PDOX models were randomized into the following groups when tumor volume reached 100 mm

Indexed as

irinotecannude miceosteosarcomaPDOXtemozolomide

Identifiers

PMID29487690
PMCPMC5814257
OpenAlexW2773499080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.